CDK6 and neoplasm: To see whether enhanced anti-tumor immunity in vivo is related to the absence of CDK6 in T cells, we subcutaneously injected Cdk6fl/fl CD4-Cre and Cdk6fl/fl mice with the colon carcinoma cell line MC38, which is surveilled by CD8+ T cells (50–52).